A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C

Hepatology

Volumn 50, Issue 4, 2009, Pages 1038-1044

  Marcolongo, Moira ^a,c   Young, Bradford ^d   Dal Pero, Francesca ^c   Fattovich, Giovanna ^b   Peraro, Laura ^b   Guido, Maria ^a   Sebastiani, Giada ^c   Palù, Giorgio ^a   Alberti, Alfredo ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; BIOPSY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; LIVER; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR;

ADULT; BIOPSY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 70350054801     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23111     Document Type: Article

References (22)

1. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Centers for Disease Control and Prevention. Division of Viral Hepatitis. US disease burden data: 1980-2003. Available at: http//www.cdc.gov. myaccess.library.utoronto.ca/ ncidod/disease/hepatitis/resource/PDFs/ disease-burden2004.pdf. Accessed January 18, 2008.
3. Seef LB, Hoonfnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-287.
4. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in chronic hepatitis C. Lancet 1997;13:975.
5. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999;31(Suppl 1):17-24.
6. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-1714.
7. Hutchison SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-1159.
8. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
9. Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
10. Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002;99:4588-4591.
11. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross-sectional and longitudinal study. Gut 2003; 52:574-579.
12. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39:1049-1055.
13. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003;125:1695-1704.
14. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004;53:318-321.
15. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. HEPATOLOGY 2003;37:493-503.
16. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis. HEPATOLOGY 2000;31:828-833.
17. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2007;46:297-306.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
19. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
20. Kim WR, Gross JB Jr, Poterucha JJ, LockeGR3rd, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. HEPATOLOGY 2001;33:201-206.
21. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-517.
22. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124: 97-104.